Study guide
12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights
Key Takeaways Explain This Topic AI
Core bioethical principles provide an indispensable framework in addictions nursing: Autonomy upholds voluntary engagement, informed consent, and self-determination; Beneficence mandates providing life-saving evidence-based MOUD; Non-Maleficence prohibits punitive discharges, forced withdrawal, and abrupt medication cessations; Justice demands equitable access and dismantling structural barriers.
Ethical and legal dilemmas in perinatal addiction care center on maternal autonomy versus state interventions; major national clinical bodies (ACOG, ASAM, ANA) unanimously oppose criminalization, forced civil detention, and punitive child welfare reporting for substance use in pregnancy, demonstrating that punitive mandates drive pregnant women away from prenatal care.
Child Abuse Prevention and Treatment Act (CAPTA) provisions emphasize Plans of Safe Care as supportive, non-punitive public health instruments designed to address infant and family healthcare needs, contrasting with adversarial child protective services reporting.
Clinical language serves as an active ethical intervention: replacing pejorative, morally loaded terminology ('dirty', 'clean', 'abuser', 'relapse') with clinically objective, person-first language ('positive toxicology screen', 'person with substance use disorder', 'recurrence of use') measurably reduces clinician bias and healthcare avoidance.
The ANA Code of Ethics with Interpretive Statements establishes an ethical obligation (Provisions 1, 3, 8, and 9) to affirm human dignity, protect patient confidentiality under 42 CFR Part 2 and HIPAA, and advocate against the systemic criminalization of substance use disorders.
Last updated: September 2026
12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights
Quick Answer: The bioethical principles of Autonomy , Beneficence , Non-Maleficence , and Justice guide advanced practice addictions nursing. Involuntary discharges, punitive dose tapers, and forced withdrawal violate non-maleficence by dramatically escalating fatal overdose risk. In perinatal care, major medical consensus ( ACOG, ASAM, ANA ) strictly opposes the criminalization of substance use during pregnancy , recognizing that punitive reporting deters prenatal care and escalates maternal-fetal morbidity; care must focus on MOUD , Plans of Safe Care , and supportive dyadic bonding ( Eat, Sleep, Console ). Person-first language is an active ethical intervention that dismantles systemic clinician bias by replacing stigmatizing jargon ("dirty," "relapse") with objective clinical terminology ("positive toxicology," "recurrence of use"). The ANA Code of Ethics mandates unconditional human dignity and social justice advocacy.
1. Foundational Bioethical Principles in Addictions Nursing
Advanced Practice Registered Nurses caring for patients with substance use disorders (SUD) operate in a complex clinical landscape where biological pathology intersects with moral judgment, societal stigma, and punitive legal frameworks. Applying the four classic bioethical principles developed by Beauchamp and Childress provides an essential analytical compass. ┌─────────────────────────────────────────────────────────────────────────────┐
- │ BIOETHICAL PILLARS IN ADDICTION CARE │
- └──────────────────────────────────────┬──────────────────────────────────────┘
- │
- ┌─────────────────────────────┼─────────────────────────────┐
- ▼ ▼ ▼
- ┌─────────────────┐ ┌─────────────────┐ ┌─────────────────┐
- │ AUTONOMY │ │ BENEFICENCE │ │ NON-MALEFICENCE │
- │ │ │ │ │ │
- │ * Self- │ │ * Provision of │ │ * Elimination of│
- │ determination │ │ first-line │ │ punitive │
- │ * Informed │ │ MOUD │ │ discharges │
- │ consent │ │ * Harm │ │ * Prevention of │
- │ * Patient-driven│ │ reduction │ │ forced │
- │ treatment │ │ engagement │ │ withdrawal │
- │ goals │ │ * Holistic care │ │ * Overdose risk │
- │ * Right of │ │ advocacy │ │ mitigation │
- │ refusal │ │ │ │ │
- └─────────────────┘ └─────────────────┘ └─────────────────┘
- │
- ▼
- ┌─────────────────┐
- │ JUSTICE │
- │ │
- │ * Equitable MOUD│
- │ distribution │
- │ * Decriminal- │
- │ ization │
- │ * Overcoming │
- │ racial bias │
- └─────────────────┘
- Autonomy
Autonomy asserts the moral and legal right of every patient to self-determination, bodily integrity, and voluntary decision-making. In addiction medicine, autonomy requires clinicians to:
Obtain rigorous informed consent , thoroughly discussing the risks, benefits, and physiological mechanisms of pharmacotherapies (e.g., explaining buprenorphine precipitated withdrawal vs. methadone retention).
Respect the patient's right to accept or decline specific interventions . Patients possess the autonomy to define their own recovery goals—whether that involves absolute abstinence, moderate consumption, or harm reduction (e.g., utilizing sterile syringes while continuing illicit opioid use).
Support decision-making capacity : Substance use disorder alone does not imply legal incompetence or lack of decision-making capacity. Except during periods of acute, severe intoxication, severe overdose delirium, or acute psychosis where immediate life-saving emergency stabilization is required, individuals with SUD retain the full ethical and legal right to direct their medical care.
Beneficence
Beneficence imposes a positive moral duty on clinicians to act in the best interest of the patient, actively promoting their health, well-being, and safety:
Initiating and maintaining evidence-based medications for opioid use disorder (MOUD) —specifically methadone and buprenorphine—which decrease all-cause mortality by 50% or more , dramatically reduce fatal overdose, and facilitate biopsychosocial stabilization.
Implementing low-barrier, patient-centered harm reduction interventions (e.g., naloxone distribution, hepatitis C and HIV treatment, infectious disease screening).
Non-Maleficence: The Ethics of Administrative Discharges
Non-Maleficence establishes the absolute ethical baseline: Primum non nocere ("First, do no harm"). In addictions nursing, some of the most catastrophic harms are iatrogenically inflicted by punitive institutional policies:
Punitive Administrative Discharges: Historically, outpatient addiction programs and residential treatment centers routinely discharged patients for "breaking program rules"—most commonly for providing a urine sample containing illicit substances. Discharging a patient with severe OUD for exhibiting the cardinal diagnostic symptom of their illness (substance use) is clinically illogical and ethically indefensible.
The Lethal Consequences of Forced Cessation: Expelling a patient from MOUD causes immediate loss of physiological tolerance. Longitudinal epidemiological data demonstrate that patients administratively terminated from buprenorphine or methadone experience an immediate 4- to 10-fold surge in fatal overdose mortality , with peak mortality occurring within the first 30 days post-discharge.
Ethical Mandate: Non-maleficence mandates that ongoing substance use must be met with treatment intensification, clinical restructuring, and harm reduction , rather than abandonment, punitive discharge, or abrupt medication cutoffs.
Justice
Justice demands fairness, equity, and the impartial distribution of healthcare resources. In addictions care, justice requires:
Confronting profound racial, ethnic, and socioeconomic disparities in addiction pharmacotherapy (e.g., studies consistently show white, commercially insured patients disproportionately receive office-based buprenorphine, while Black, Hispanic, and low-income patients are disproportionately relegated to highly restricted, stigmatized urban methadone clinics or incarceration).
Challenging the systemic criminalization of substance use disorders , shifting societal resources from carceral punishment to public health infrastructure.
2. Ethical and Legal Dilemmas in Perinatal Addiction Medicine
Few areas of healthcare generate more contentious ethical conflicts than substance use during pregnancy. Advanced practice nurses must navigate the competing interests of maternal autonomy and fetal protection. ┌─────────────────────────────────────────────────────────────────────────────┐
- │ PERINATAL ADDICTION CARE PARADIGM │
- └──────────────────────────────────────┬──────────────────────────────────────┘
- │
- ┌─────────────────────────────┴─────────────────────────────┐
- ▼ ▼
- ┌─────────────────────────────────┐ ┌─────────────────────────────────┐
- │ PUNITIVE CARCERAL MODEL │ │ EVIDENCE-BASED HEALTH MODEL │
- ├─────────────────────────────────┤ ├─────────────────────────────────┤
- │ * Criminal prosecution & arrest │ │ * Voluntary engagement & trust │
- │ * Child abuse / endangerment │ │ * First-line MOUD (Bup/Meth) │
- │ criminal statutes │ │ * Comprehensive prenatal care │
- │ * Mandatory punitive reporting │ │ * Plans of Safe Care (CAPTA) │
- │ * Consequences: Concealment, │ │ * Eat, Sleep, Console (ESC) │
- │ avoidance of prenatal visits, │ │ * Consequences: Optimized │
- │ catastrophic maternal-fetal │ │ gestational age, reduced NAS │
- │ morbidity & fatal overdoses │ │ severity, family preservation │
- └─────────────────────────────────┘ └─────────────────────────────────┘
- The Failure of the Punitive Model
Over the past three decades, numerous state legislatures have enacted punitive measures criminalizing substance use during pregnancy, utilizing charges ranging from "chemical endangerment" to child neglect, fetal abuse, or involuntary civil commitment. The ethical and epidemiological fallacies of this approach are profound:
Deterrence from Healthcare: When pregnant individuals fear that disclosing substance use or presenting for prenatal visits will trigger criminal arrest, incarceration, or immediate loss of child custody, they systematically avoid healthcare . They miss critical obstetrical ultrasounds, fail to receive treatment for gestational complications, avoid prenatal vitamins, and conceal substance use until active labor.
Severe Perinatal Outcomes: Avoiding prenatal care leads to unmonitored cycles of acute intoxication and severe withdrawal. Maternal opioid withdrawal precipitates fetal distress, placental abruption, meconium aspiration, intrauterine growth restriction (IUGR), premature labor, and fetal demise.
Violation of Bodily Autonomy: Treating a pregnant woman as an adversarial vessel rather than an autonomous patient violates fundamental constitutional and bioethical rights.
Professional Medical and Nursing Consensus
Every major medical, obstetrical, and nursing organization in the United States—including the American College of Obstetricians and Gynecologists (ACOG) , the American Society of Addiction Medicine (ASAM) , the American Nurses Association (ANA) , and the March of Dimes —has issued formal policy statements condemning the criminalization of substance use in pregnancy .
Standard of Care: The established gold standard of care for opioid use disorder during pregnancy is pharmacotherapy with methadone or buprenorphine combined with comprehensive obstetrical and psychosocial support. Detoxification or medically supervised withdrawal during pregnancy is associated with high relapse rates (>70%–90%) and worse perinatal outcomes.
Plans of Safe Care (CAPTA): Under the federal Child Abuse Prevention and Treatment Act (CAPTA) , states are mandated to develop "Plans of Safe Care" for infants identified as affected by substance abuse, withdrawal symptoms, or fetal alcohol spectrum disorders. Best clinical practice dictates that Plans of Safe Care must function as supportive, multidisciplinary public health tools —connecting the mother-infant dyad to lactation support, housing, pediatric follow-up, and MOUD—rather than automated referrals to punitive child welfare enforcement.
Neonatal Care Innovations (Eat, Sleep, Console): Modern management of Neonatal Opioid Withdrawal Syndrome (NOWS) has transitioned from rigid numerical scoring systems (such as the Finnegan scale) to the Eat, Sleep, Console (ESC) model. ESC emphasizes non-pharmacological interventions, parental rooming-in, breastfeeding, skin-to-skin contact, and low-stimulation environments, reducing neonatal intensive care unit (NICU) admissions and neonatal morphine exposure by more than 50%.
3. Combating Stigma: Language as an Ethical Clinical Intervention
Stigma is not merely a social inconvenience; it is a lethal, structural barrier that permeates the healthcare delivery system. Biased clinical attitudes lead directly to diagnostic overshadowing, delayed intervention, substandard analgesia, and premature patient discharge.
Person-First and Clinically Accurate Terminology
Language is an ethical intervention. Research demonstrates that when clinicians describe a patient using pejorative language (e.g., "substance abuser"), fellow healthcare professionals are significantly more likely to judge the patient as personally culpable, view them as a social threat, and recommend punitive disciplinary action rather than medical treatment. APRNs must model and enforce person-first, destigmatizing terminology across all oral presentations and electronic health record (EHR) documentation:
Stigmatizing / Pejorative Term Clinically Accurate / Person-First Term Bioethical & Clinical Rationale
"Addict," "Junkie," "Abuser" "Person with a substance use disorder (SUD)" or "Patient with severe OUD" Defines the human being first, treating the condition as a medical illness rather than an immutable moral identity.
"Clean" (referring to urine) "Negative urine toxicology" or "Results consistent with prescribed regimen" Biological fluids are not morally "clean" or "dirty"; eliminates moralistic connotations of purity versus contamination.
"Dirty" (referring to urine) "Positive urine toxicology for [substance]" or "Inconsistent with prescribed medications" Provides objective, precise diagnostic terminology without implying personal failure, deceit, or moral filth.
"Relapse" "Recurrence of use," "Return to use," or "Symptom recurrence" Frames substance use as a characteristic cycle of a chronic, remitting-relapsing medical disease, rather than a catastrophic moral defeat.
"Substance Abuse" "Substance use," "Substance misuse," or "Substance use disorder" "Abuse" implies willful malice, criminality, and violence, activating punitive biases among clinicians and judicial systems.
"Replacement / Substitution Therapy" "Medication for Opioid Use Disorder (MOUD)" or "Opioid Agonist Pharmacotherapy" Dispels the false stigma that patients are "trading one addiction for another"; validates MOUD as standard pharmacological therapy.
"Non-compliant" / "Refusing care" "Declining current intervention" or "Experiencing barriers to treatment adherence" Respects patient autonomy; reframes adherence as an ongoing collaborative negotiation rather than authoritarian obedience.
4. The ANA Code of Ethics Applied to Vulnerable Populations
The American Nurses Association (ANA) Code of Ethics for Nurses with Interpretive Statements establishes the non-negotiable ethical benchmark for professional nursing practice. Several specific provisions apply directly to advanced practice addictions nursing:
Provision 1: Unconditional Human Dignity
"The nurse practices with compassion and respect for the inherent dignity, worth, and unique attributes of every person."
Clinical Application: The APRN delivers compassionate, unbiased care to all individuals, regardless of active substance use, criminal history, housing status, or past treatment non-adherence. Clinicians must actively check and eliminate their personal biases, ensuring that individuals who inject drugs receive identical clinical empathy, thorough physical examinations, and evidence-based care as patients with other chronic illnesses like diabetes or cardiovascular disease.
Provision 2: Primary Commitment to the Patient
"The nurse's primary commitment is to the patient, whether an individual, family, group, community, or population."
Clinical Application: When external pressures arise—such as law enforcement seeking patient disclosures, employers requesting drug test results, or child protective services demanding medical records—the APRN's primary allegiance remains firmly anchored to the patient's health and confidentiality, bounded by federal statutory privacy protections.
- Provision 3: Advocacy, Safety & Confidentiality (42 CFR Part 2)
- "The nurse promotes, advocates for, and protects the rights, health, and safety of the patient."
Confidentiality under 42 CFR Part 2: Recognizing the profound criminal and social penalties associated with substance use, federal law under 42 CFR Part 2 provides stringent privacy protections for substance use disorder patient records that far exceed standard HIPAA rules. Information regarding SUD diagnosis, treatment, or referral cannot be disclosed to law enforcement, courts, employers, or third parties without explicit, specialized written patient consent or a specialized court order demonstrating extraordinary cause.
Provisions 8 and 9: Social Justice and Health Disparities
"The nurse collaborates with other health professionals and the public to protect human rights, promote health diplomacy, and reduce health disparities... The profession of nursing, collectively through its professional organizations, must articulate nursing values, maintain the integrity of the profession, and integrate principles of social justice into nursing and health policy."
Advocacy for Decriminalization: The APRN actively engages in institutional and public policy advocacy to dismantle carceral approaches to addiction, eliminate racially discriminatory sentencing laws, expand harm reduction infrastructure (e.g., legalizing Syringe Service Programs and Overdose Prevention Centers), and guarantee universal access to MOUD in all correctional facilities.